Journal News

Rare genetic mutation in Amish population linked to ‘bad’ cholesterol levels

Farah Aziz Annesha
May 28, 2024

Low-density lipoprotein, or LDL, is commonly called “bad” cholesterol since high levels of LDL contribute to a higher risk of coronary heart disease.

A recent study conducted on Amish people, who are unique for genetic studies due to their isolation from the general population, shows a direct association between a novel genetic mutation in the SORT1 gene and human LDL levels. SORT1 is a gene that encodes for the protein sortilin, which previous studies suggest might influence LDL levels. However, functional studies on the gene have so far led to contradictory results.

Researchers working on this study were invited to dinners in the homes of the Amish study participants.
Kelly Mitok
Researchers working on this study were invited to dinners in the homes of the Amish study participants.

In collaboration with the University of Maryland Amish Research Clinic, this new study led by Kelly Mitok and colleagues at the University of Wisconsin–Madison is the first to establish a direct link between the SORT1 gene and LDL cholesterol.

This discovery can be informative for doctors, especially those who practice precision or personalized medicine. Like clothing that is custom-made to fit a person according to their measurements, precision medicine aims to provide tailored treatments and preventive measures according to an individual’s unique genomic data, environment and lifestyle.

“Every discovery that is made, including ours, is being added continuously to a library of information about the effect each genetic mutation has on humans,” Mitok said. “So when a patient has a SORT1 gene mutation, the doctor can suggest preventive treatment to help reduce their risk of coronary heart disease, because now they know that this SORT1 mutation is linked to LDL levels.”

Working in Alan Attie’s lab, Mitok began her work on SORT1 by studying links between SORT1 mutations and Type 2 diabetes. However, progress has been slow with little result. Searching for a new focus, Attie and Mitok asked their colleagues at the Amish Research Clinic if they had found any links between SORT1 mutations and diabetes.
The genetic studies staff informed them of links between SORT1 and LDL-cholesterol.

The researchers collected blood samples from clinical trial participants at the Amish Research Clinic and then conducted whole exome sequencing on the samples. This DNA sequencing technique is used to locate mutations within the exomic, or coding, region of the genome. They also performed clinical lipid panels to measure LDL cholesterol levels. Mitok and her team analyzed these data sets, looking for conclusive evidence for any links between the two.

Their findings, reported in an article in the Journal of Lipid Research, showed that one coding mutation in the SORT1gene, called K302E, led to higher levels of LDL cholesterol in the Amish. However, mice studies with this mutation showed contradictory results. An explanation for the contradiction could be due to the difference in metabolism between the two species. This invaluable study will be crucial in informing future research on SORT1gene and its effect on human LDL cholesterol.

Mitok traveled from the University of Wisconsin–Madison to the Old Order Amish community in Lancaster County, Pennsylvania, where she presented her team’s findings to researchers at the Amish Research Clinic and members of the Amish community. She also assisted a member of the clinic in going house to house to recruit Amish individuals to participate in the next clinical study.

“The most rewarding aspect was how this went beyond just getting some data for research,” Mitok said, “It was how the Amish community trusted us like family, inviting us to dinners at their homes and actively participating in the study. This is due to the strong personal connections that the founder and director of the Amish Research Program, Dr. Alan Shuldiner, built with the Amish community from the start.”

Enjoy reading ASBMB Today?

Become a member to receive the print edition monthly and the digital edition weekly.

Learn more
Farah Aziz Annesha

Farah Aziz Annesha is an aspiring science writer. She recently graduated from Yonsei University Underwood International College with a B.S. in biotechnology and a B.A. in comparative literature.

Related articles

From the journals: JLR
Vaishnavi Muralikrishnan
From the journals: JLR
Sephra Rampersad
From the journals: JLR
Poornima Sankar
From the journals: JLR
Swarnali Roy

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

The quest to treat and cure xerostomia
Interview

The quest to treat and cure xerostomia

July 23, 2024

Blake Warner, chief of the Salivary Disorders Unit at the NIH talks about his lab’s efforts to develop treatments for dry mouth.

There's more to blue cheese than just the stench
News

There's more to blue cheese than just the stench

July 21, 2024

Virginia Tech researchers discovered a way to synthesize a compound in the mold of blue cheese that has antibacterial and anticancer properties.

Engineering cells to broadcast their behavior can help scientists study their inner workings
News

Engineering cells to broadcast their behavior can help scientists study their inner workings

July 20, 2024

Researchers can use waves to transmit signals from the invisible processes and dynamics underlying how cells make decisions.

From the journals: JBC
Journal News

From the journals: JBC

July 19, 2024

Lung cancer cells resist ferroptosis. ORMDL3 in ulcerative colitis. Novel genetic variants in thyroid cancer. Read about these recent papers.

Seeking the sweet spot to beat a pig parasite
Journal News

Seeking the sweet spot to beat a pig parasite

July 16, 2024

Researchers extracted, separated and tested glycans from the porcine whipworm in an effort to determine the best way to develop treatments and vaccines.

Radioactive drugs strike cancer with precision
News

Radioactive drugs strike cancer with precision

July 14, 2024

The tumor-seeking radiopharmaceuticals are charting a new course in oncology, with promise for targeted treatments with fewer side effects.